Familial Cancer

, Volume 13, Issue 1, pp 1–12

Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review


DOI: 10.1007/s10689-013-9671-6

Cite this article as:
Metcalf, A.M. & Spurdle, A.B. Familial Cancer (2014) 13: 1. doi:10.1007/s10689-013-9671-6


Colorectal cancer (CRC) that displays high microsatellite instability (MSI-H) can be caused by either germline mutations in mismatch repair (MMR) genes, or non-inherited transcriptional silencing of the MLH1 promoter. A correlation between MLH1 promoter methylation, specifically the ‘C’ region, and BRAF V600E status has been reported in CRC studies. Germline MMR mutations also greatly increase risk of endometrial cancer (EC), but no systematic review has been undertaken to determine if these tumour markers may be useful predictors of MMR mutation status in EC patients. Endometrial cancer cohorts meeting review inclusion criteria encompassed 2675 tumours from 20 studies for BRAF V600E, and 447 tumours from 11 studies for MLH1 methylation testing. BRAF V600E mutations were reported in 4/2675 (0.1 %) endometrial tumours of unknown MMR mutation status, and there were 7/823 (0.9 %) total sequence variants in exon 11 and 27/1012 (2.7 %) in exon 15. Promoter MLH1 methylation was not observed in tumours from 32 MLH1 mutation carriers, or for 13 MSH2 or MSH6 mutation carriers. MMR mutation-negative individuals with tumour MLH1 and PMS2 IHC loss displayed MLH1 methylation in 48/51 (94 %) of tumours. We have also detailed specific examples that show the importance of MLH1 promoter region, assay design, and quantification of methylation. This review shows that BRAF mutations occurs so infrequently in endometrial tumours they can be discounted as a useful marker for predicting MMR-negative mutation status, and further studies of endometrial cohorts with known MMR mutation status are necessary to quantify the utility of tumour MLH1 promoter methylation as a marker of negative germline MMR mutation status in EC patients.


Endometrial cancerLynch syndromeMLH1 methylationBRAF V600E



Endometrial cancer


Microsatellite instability


Mismatch repair


Colorectal cancer


Lynch syndrome


Multiplex ligation-dependent probe amplification




Microsatellite stable

Supplementary material

10689_2013_9671_MOESM1_ESM.docx (142 kb)
Supplementary material 1 (DOCX 142 kb)
10689_2013_9671_MOESM2_ESM.docx (32 kb)
Supplementary material 2 (DOCX 32 kb)

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of Genetics and Computational BiologyQueensland Institute of Medical ResearchHerstonAustralia